Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy. - Archive ouverte HAL Access content directly
Journal Articles Oncogene Year : 2014

Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.

(1) , (1) , (1) , (1) , (1) , (1) , (1) , (2) , (1) , (1) , (2) , (3, 4, 5) , (1) , (1)
1
2
3
4
5
Nina Radosevic-Robin

Abstract

AXL receptor tyrosine kinase (RTK) is implicated in proliferation and invasion of many cancers, particularly in pancreatic ductal adenocarcinoma (PDAC), for which new therapeutic options are urgently required. We investigated whether inhibition of AXL activity by specific monoclonal antibodies (mAbs) is efficient in limiting proliferation and migration of pancreatic cancer cells. Expression of AXL was evaluated by immunohistochemistry in 42 PDAC. The AXL role in oncogenesis was studied using the short hairpin RNA approach in a pancreatic carcinoma cell line. We further generated antihuman AXL mAbs and evaluated their inhibitory effects and the AXL downstream signaling pathways first in vitro, in a panel of pancreatic cancer cell lines and then in vivo, using subcutaneous or orthotopic pancreatic tumor xenografts. AXL receptor was found expressed in 76% (32/42) of PDAC and was predominantly present in invasive cells. The AXL-knockdown Panc-1 cells decreased in vitro cell migration, survival and proliferation, and reduced in vivo tumor growth. Two selected anti-AXL mAbs (D9 and E8), which inhibited phosphorylation of AXL and of its downstream target AKT without affecting growth arrest-specific factor 6 (GAS6) binding, induced downexpression of AXL by internalization, leading to an inhibition of proliferation and migration in the four pancreatic cancer cell lines studied. In vivo, treatment by anti-AXL mAbs significantly reduced growth of both subcutaneous and orthotopic pancreatic tumor xenografts independently of their KRAS mutation status. Our in vitro and preclinical in vivo data demonstrate that anti-human AXL mAbs could represent a new approach to the pancreatic cancer immunotherapy.Oncogene advance online publication, 18 November 2013; doi:10.1038/onc.2013.487.
Fichier principal
Vignette du fichier
Supplementary_information.pdf (157.62 Ko) Télécharger le fichier
Vignette du fichier
Figures_WL2.pdf (1.58 Mo) Télécharger le fichier
Vignette du fichier
Leconet_et_al-Oncogene-Final.pdf (307.37 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)
Origin : Files produced by the author(s)

Dates and versions

inserm-00916587 , version 1 (16-05-2014)

Identifiers

Cite

Wilhem Leconet, Christel Larbouret, Thierry Chardès, Gaëlle Thomas, Madeline Neiveyans, et al.. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.: Anti-AXL mAb for pancreatic cancer immunotherapy. Oncogene, 2014, 33 (47), pp.5405-14. ⟨10.1038/onc.2013.487⟩. ⟨inserm-00916587⟩
434 View
1257 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More